Intratumoral Delivery of a Novel Oncolytic Adenovirus Encoding Human Antibody against PD-1 Elicits Enhanced Antitumor Efficacy

Researchers constructed an innovative oncolytic virus (OV) based on a chimpanzee adenoviral vector with low seropositivity in the human population, named AdC68-spE1A-αPD-1, which endowed the parental OV with the ability to express full-length anti-human programmed cell death-1 monoclonal antibody.